Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764699 | 0.95 | HRH3 (0.49) | HRH3BTKSMN1; SMN2KMT2AHTT | |
| SCHEMBL28655866 | 0.93 | HRH3 (0.47) | HRH3BTKSMN1; SMN2KMT2AHTT | |
| SCHEMBL1409272 | 0.93 | HRH3 (0.47) | HRH3BTKSMN1; SMN2KMT2AHTT | |
| SCHEMBL28172293 | 0.93 | HRH3 (0.47) | HRH3BTKSMN1; SMN2KMT2AHTT | |
| Hydrochloric Acid SCHEMBL27793145 | 0.93 | HRH3 (0.47) | HRH3BTKSMN1; SMN2KMT2AHTT | |
| SCHEMBL31356450 | 0.93 | HRH3 (0.47) | HRH3BTKSMN1; SMN2KMT2AHTT | |
| SCHEMBL11752523 | 0.93 | HRH3 (0.47) | HRH3BTKSMN1; SMN2KMT2AHTT | |
| Formic Acid SCHEMBL28215972 | 0.92 | HRH3 (0.44) | HRH3BTKSMN1; SMN2KMT2AHTT | |
| SCHEMBL25762342 | 0.91 | BTK (0.50) | HRH3BTKSMN1; SMN2KMT2AHTT | |
| SCHEMBL1296378 | 0.91 | BTK (0.50) | HRH3BTKSMN1; SMN2KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115536623-A | Synthetic method of 3-cyclotetramethylene benzofuran derivative | 南通大学 | 2022-12-30 | — | — | CN | claimed |
| CN-105294546-B | A kind of pyridine compounds and preparation method thereof | 天津市斯芬克司药物研发有限公司 | 2017-12-08 | — | — | CN | claimed |
| CN-112189010-B | Triazole N-linked carbamoyl cyclohexyl acid as LPA antagonists | 百时美施贵宝公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12304913-B2 | Dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2025-05-20 | — | — | US | disclosed |
| US-12209072-B2 | Cyclopentyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-28 | — | — | US | disclosed |
| US-12195444-B2 | Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| CN-118955473-A | Difunctional compounds for degrading BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240317686-A1 | RORyT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2024-09-26 | — | — | US | disclosed |
| EP-4408843-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | Viva Star Biosciences (Suzhou) Co., Ltd. (CN) | 2024-08-07 | — | — | EP | disclosed |
| CN-113412259-B | Difunctional compounds for degrading BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | disclosed |
| CN-101801376-A | Pyrazolo (3,4-b) pyridine derivatives as phosphodiesterase inhibitors | RANBAXY LAB LTD | 2010-08-11 | — | — | CN | disclosed |
| US-20090018184-A1 | Polyether Brevetoxin Derivatives as a Treatment for Cystic Fibrosis, Mucociliary Dysfunction, and Pulmonary Diseases | UNIVERSITY OF NORTH CAROLINA AT WILMINGTON | 2009-01-15 | — | — | US | disclosed |
| CN-101321738-A | Spirocyclic derivatives | PFIZER LTD (GB) | 2008-12-10 | — | — | CN | disclosed |
| US-7399782-B2 | Polyether brevetoxin derivatives as a treatment for cystic fibrosis, mucociliary dysfunction, and pulmonary diseases | UNIVERSITY OF NORTH CAROLINA AT WILMINGTON (US) | 2008-07-15 | — | — | US | disclosed |
| US-20070036258-A1 | Process for producing radioactive fluorine compound | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| CN-1419541-A | Pharmaceutically active pyrrolidine derivatives as BAX inhibitors | APPLIED RES SYSTEMS AKS HOLDIN (NL) | 2003-05-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | HRH3 3423/4885BTK 3278/4885SMN1; SMN2 2104/4885 |
| US-12209072-B2 | Cyclopentyl acids as LPA antagonists | LPAR1, LPAR5, LPAR2 | HRH3 873/4885BTK 3029/4885SMN1; SMN2 4240/4885 |
| US-20090018184-A1 | Polyether Brevetoxin Derivatives as a Treatment for Cystic Fibrosis, Mucociliary Dysfunction, and Pulmonary Diseases | CFTR, MUC1, SLC47A1 | HRH3 2493/4885BTK 2554/4885SMN1; SMN2 3290/4885 |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR5 | HRH3 50/4885BTK 934/4885SMN1; SMN2 1771/4885 |
| US-12304913-B2 | Dihydropyrrolopyrazole derivative | CBR3, SLC13A3, CYP3A5 | HRH3 363/4885BTK 2594/4885SMN1; SMN2 3368/4885 |
| US-20240317686-A1 | RORyT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | RORC, RORB, RORA | HRH3 2047/4885BTK 1910/4885SMN1; SMN2 4471/4885 |
| US-20070036258-A1 | Process for producing radioactive fluorine compound | AFF1, AFF4, RER1 | HRH3 236/4885BTK 2358/4885SMN1; SMN2 1776/4885 |
| US-12195444-B2 | Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | HRH3 207/4885BTK 1782/4885SMN1; SMN2 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.